Hyaluronate sodium for knee osteoarthritis :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

Use of intra-articular Hyaluronate sodium for management of knee osteoarthritis

HA for knee OA HA for knee OA
HA for knee OA HA for knee OA

The objective of this non-interventional observational study was to assess the effectiveness, safety, and tolerability of Hyaluronate sodium in treating osteoarthritis among patients with comorbid pathology.

See All

Key take away

In patients with primary knee osteoarthritis, intra-articular Hyaluronate sodium injections effectively reduce joint pain, stiffness, and the need for daily NSAIDs.

Background

The objective of this non-interventional observational study was to assess the effectiveness, safety, and tolerability of Hyaluronate sodium in treating osteoarthritis among patients with comorbid pathology.

Method

The study involved 30 volunteers between the ages of 40 and 65 who had stage II-III osteoarthritis of the knee. These individuals were treated with Hyaluronate sodium, and their condition was evaluated using the Kellgren-Lawrence scale. The treatment course consisted of three standard intra-articular injections of a sterile sodium Hyaluronate gel derived from microbial fermentation, administered once a week.

Throughout the assessment, volunteers were asked to continue their non-steroidal anti-inflammatory drug (NSAID) therapy at stable standard dosages. The efficacy of the intervention was evaluated by monitoring alterations in various factors, including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) index, Visual analog scale (VAS) pain scores during movement and at rest, goniometry data, as well as the results of a stair climb test and a 30-meter walking test.

Result

Observations revealed a favorable impact of the treatment on multiple aspects. These included notable improvements in pain levels based on the VAS, improved performance on functional tests, and higher scores on the WOMAC index. Encouragingly, the positive changes in the evaluated parameters became evident as early as the seventh day of therapy. During the therapy, no adverse reactions were noted. Furthermore, the tolerability to the drug was good.

Conclusion

Patients diagnosed with moderate joint dysfunction in the II-III stages of knee osteoarthritis can benefit from the utilization of Hyaluronate sodium as a treatment option.

Source:

HERALD of North-Western State Medical University named after II Mechnikov

Article:

Treatment of patients with knee osteoarthritis with Hyaluronate sodium (Revisk) in clinical practice

Authors:

Shostak M.S et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: